A Phase I Trial of Panobinostat (LBH589) and Epirubicin in Patients With Solid Tumor Malignancies.

Trial Profile

A Phase I Trial of Panobinostat (LBH589) and Epirubicin in Patients With Solid Tumor Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Epirubicin (Primary) ; Panobinostat (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Mar 2016 Status changed from active, no longer recruiting to completed, according to results published in the Annals of Oncology.
    • 12 Feb 2016 Results published in the Annals of Oncology
    • 18 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top